News for AVTX Stock

Avalo Therapeutics to Participate in Upcoming Investor Conferences Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors Avalo Therapeutics to Participate in Upcoming Investor Conferences Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates Avalo Therapeutics to Participate in The Citizens Life Sciences Conference Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board Avalo Reports 2024 Financial Results and Recent Business Updates Avalo Therapeutics to Participate in Upcoming Investor Conferences Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants Avalo Therapeutics to Present at Upcoming Investor Conferences Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa Avalo Announces Participation in September Investor Conferences Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates Avalo Therapeutics Appoints Biotech Leaders to Board of Directors Avalo Reports 2023 Financial Results and Provides Business Updates Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million Avalo Therapeutics Announces 1-for-240 Reverse Stock Split Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates Avalo Completes Divestiture of AVTX-800 Series Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation Avalo Enters into Agreement to Divest AVTX-800 Series Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates Avalo to Participate in SVB Securities Therapeutics Forum Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma Avalo to Present at the Jefferies Healthcare Conference Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board Avalo to Present at ATS 2023 Respiratory Innovation Summit Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates Avalo Reports 2022 Financial Results and Provides Business Updates Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage Avalo to Present at the H.C. Wainwright Global Investment Conference Avalo Therapeutics Announces Board Changes Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II) Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split Avalo to Present at the 2022 Jefferies Healthcare Conference Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA) Avalo to Present at the H.C. Wainwright Global Life Sciences Conference Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates Avalo Therapeutics Announces Leadership Transition Avalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022 Avalo Appoints Two New Independent Directors to Its Board Avalo to Present at Two Upcoming Conferences Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates Avalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit Horizon Technology Finance Provides Third Quarter 2021 Portfolio Update Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock